- Home
- IT vs PEN Comparison
IT vs PEN Comparison
Compare IT & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IT | PEN |
|---|---|---|
| Founded | 1979 | 2004 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.8B |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IT | PEN |
|---|---|---|
| Price | $230.51 | $324.78 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 17 |
| Target Price | $189.54 | ★ $362.54 |
| AVG Volume (30 Days) | ★ 767.1K | 309.3K |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1155.56 |
| EPS | ★ 7.29 | 1.70 |
| Revenue | ★ $2,021,441,000.00 | $1,403,665,000.00 |
| Revenue This Year | N/A | $13.46 |
| Revenue Next Year | $4.02 | $13.01 |
| P/E Ratio | ★ $31.97 | $191.31 |
| Revenue Growth | 13.30 | ★ 17.50 |
| 52 Week Low | $124.25 | $221.26 |
| 52 Week High | $257.69 | $362.41 |
Technical Indicators
Market Signals| Indicator | IT | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 72.98 | 64.47 |
| Support Level | $221.16 | $315.42 |
| Resistance Level | N/A | $329.14 |
| Average True Range (ATR) | 7.32 | 1.95 |
| MACD | 3.95 | 0.77 |
| Stochastic Oscillator | 92.12 | 91.72 |
Price Performance
Historical ComparisonAbout IT Gartner Inc.
Gartner provides independent research and analysis on information technology for chief information officers and other business executives who help plan companies' IT budgets. Its flagship Magic Quadrant reports inform many enterprises of their IT procurement decisions. Gartner also provides consulting services and holds some of the largest conferences in the IT industry. Around 80% of Gartner's revenue is generated from industry research.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.